Important New Measures to Reduce Risks of Valproate in Pregnancy

The Medicines and Healthcare products Regulatory Agency (MHRA) has changed the licence for valproate medicines (Epilim, Depakote and generic brands), in that they are contraindicated and must no longer be prescribed to women or girls of childbearing potential unless they are on the pregnancy prevention programme (PPP).

The UK’s Chief Medical Officers will be issuing instructions and educational materials to support the implementation of the PPP, which will be sent to GPs in the coming weeks.

See attached a letter from the MHRA to the GPC, a letter sent to practices, and access a link to their press release.

Thank you